Inflammatory bowel diseases · 2025
How Should an IBD Prevention Trial Be Designed?
СтатьяОбзорПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Goetgebuer Rogier L, Ungaro Ryan C, Feagan Brian G, Jairath Vipul, Colombel Jean-Frédéric, D'Haens Geert R A M
Аннотация
BACKGROUND: Advances in understanding disease pathogenesis have revealed a preclinical phase of inflammatory bowel disease (IBD), offering a potential window for preventive measures. There is growing interest in trials to prevent IBD in at-risk individuals. However, there is limited guidance on how to set up prevention trials in IBD. This review aims to outline key considerations for designing an IBD prevention trial.
METHODS: We conducted a review of the literature, gaining insight from prevention trials in other immune-mediated inflammatory diseases (IMIDs). We focused on considerations to set up a secondary prevention trial regarding design, risk stratification and selection strategies, inclusion and exclusion criteria, endpoints, and ethical considerations.
RESULTS: Across IMIDs in which features predictive of future risk have been identified, trials have leveraged well-characterized at-risk cohorts, biomarkers for disease prediction, and feasible interventions. Key elements to consider include (1) identification and longitudinal monitoring of at-risk individuals based on biomarkers, (2) clear definitions of inclusion and exclusion criteria distinguishing a primary prevention trial to prevent disease in at-risk individuals from a secondary prevention trial in individuals with signs of subclinical disease, (3) use of time-to-event endpoints, (4) risk-benefit balancing in intervention choice, and (5) engagement of at-risk individuals. In IBD, analogous strategies are emerging and first-degree relatives stand out as a group for screening. Significant challenges remain in defining risk thresholds, optimizing endpoints, and selected interventions.
CONCLUSION: Prevention trials in IBD hold promise but require careful design informed by experiences from other IMIDs. Central to this effort are the development of validated predictive tools, ethically appropriate interventions, and international collaboration to assemble well-powered at-risk cohorts.
METHODS: We conducted a review of the literature, gaining insight from prevention trials in other immune-mediated inflammatory diseases (IMIDs). We focused on considerations to set up a secondary prevention trial regarding design, risk stratification and selection strategies, inclusion and exclusion criteria, endpoints, and ethical considerations.
RESULTS: Across IMIDs in which features predictive of future risk have been identified, trials have leveraged well-characterized at-risk cohorts, biomarkers for disease prediction, and feasible interventions. Key elements to consider include (1) identification and longitudinal monitoring of at-risk individuals based on biomarkers, (2) clear definitions of inclusion and exclusion criteria distinguishing a primary prevention trial to prevent disease in at-risk individuals from a secondary prevention trial in individuals with signs of subclinical disease, (3) use of time-to-event endpoints, (4) risk-benefit balancing in intervention choice, and (5) engagement of at-risk individuals. In IBD, analogous strategies are emerging and first-degree relatives stand out as a group for screening. Significant challenges remain in defining risk thresholds, optimizing endpoints, and selected interventions.
CONCLUSION: Prevention trials in IBD hold promise but require careful design informed by experiences from other IMIDs. Central to this effort are the development of validated predictive tools, ethically appropriate interventions, and international collaboration to assemble well-powered at-risk cohorts.